Sign in or create an account to add this stock to your watchlist.
About Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is eravacycline, a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections. It conducted Phase III clinical trials with eravacycline through investigating Gram-negative infections treated with eravacycline (IGNITE). The company has completed IGNITE1 and IGNITE4, a Phase III clinical trial evaluating the safety and efficacy of eravacycline with IV administration for the treatment of complicated intra-abdominal infections; IGNITE2, a Phase III clinical trial evaluating the safety and efficacy of eravacycline with IV-to-oral transition therapy for the treatment of complicated urinary tract infections (cUTI); and IGNITE3, a Phase III clinical trial evaluating the safety and efficacy of eravacycline with IV administration for the treatment of cUTI. It is also developing TP-271, a synthetic broad-spectrum fluorocycline that is in Phase I clinical trial for respiratory diseases caused by bacterial biothreat pathogens; and TP-6076, a synthetic fluorocycline derivative, which is in Phase I clinical trial for multidrug-resistant Gram-negative infections. Tetraphase Pharmaceuticals, Inc. has a license agreement with Everest Medicines Limited to develop and commercialize eravacycline for the treatment of complicated intra-abdominal infections and other indications in mainland China, Taiwan, Hong Kong, Macau, South Korea, and Singapore. The company was founded in 2006 and is headquartered in Watertown, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TTPH
CUSIPN/A
Phone617-715-3600
Debt
Debt-to-Equity RatioN/A
Current Ratio7.43
Quick Ratio7.43
Price-To-Earnings
Trailing P/E Ratio-1.38
Forward P/E Ratio-2.41
P/E GrowthN/A
Sales & Book Value
Annual Sales$9.67 million
Price / Sales20.06
Cash FlowN/A
Price / CashN/A
Book Value$2.17 per share
Price / Book1.73
Profitability
EPS (Most Recent Fiscal Year)($2.63)
Net Income$-114,750,000.00
Net Margins-1,061.06%
Return on Equity-85.70%
Return on Assets-73.93%
Miscellaneous
Employees78
Outstanding Shares51,600,000
Tetraphase Pharmaceuticals (NASDAQ:TTPH) Frequently Asked Questions
What is Tetraphase Pharmaceuticals' stock symbol?
Tetraphase Pharmaceuticals trades on the NASDAQ under the ticker symbol "TTPH."
How were Tetraphase Pharmaceuticals' earnings last quarter?
Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) announced its quarterly earnings data on Thursday, May, 3rd. The biopharmaceutical company reported ($0.42) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.46) by $0.04. The biopharmaceutical company had revenue of $1.89 million for the quarter, compared to the consensus estimate of $1.88 million. Tetraphase Pharmaceuticals had a negative return on equity of 85.70% and a negative net margin of 1,061.06%. View Tetraphase Pharmaceuticals' Earnings History.
When is Tetraphase Pharmaceuticals' next earnings date?
What price target have analysts set for TTPH?
9 Wall Street analysts have issued 1 year price targets for Tetraphase Pharmaceuticals' shares. Their forecasts range from $3.00 to $11.00. On average, they expect Tetraphase Pharmaceuticals' stock price to reach $7.1429 in the next year. View Analyst Ratings for Tetraphase Pharmaceuticals.
What are Wall Street analysts saying about Tetraphase Pharmaceuticals stock?
Here are some recent quotes from research analysts about Tetraphase Pharmaceuticals stock:
- 1. HC Wainwright analysts commented, "and Likely Commercial Uptake in cIAI; Affirm Buy Stock Data 05/03/2018 Price $3.15 Exchange NASDAQ Price Target $6.00 52-Week High $8.75 52-Week Low $2.05 Enterprise Value (M) $45.3 Market Cap (M) $163 Public Market Float (M) 37.5 Shares Outstanding (M) 51.6 3 Month Avg Volume 1,678,640 Short Interest (M) 3.41 Shares Outstanding (M): Figure shown is as of May 2, 2018. Balance Sheet Metrics Cash (M) $117.7 Total Debt (M) $0.0 Total Cash/Share $2.28 Book Value/Share $1.93 Cash (M): Figure shown is as of March 31, 2018. EPS Diluted Full Year – Dec 2016A 2017A 2018E 1Q (0.46) (0.79) (0.42)A 2Q (0.47) (0.83) (0.37) 3Q (0.58) (0.63) (0.31) 4Q (0.61) (0.46) (0.24) FY (2.11) (2.63) (1.32) Revenue ($M) Full Year – Dec 2016A 2017A 2018E 1Q 2.0 1.5 1.9A 2Q 1.2 1.6 2.0 3Q 0.9 4.1 1.8 4Q 1.1 2.5 1.5 FY 5.1 9.7 7.2 10 8 6 4 2 0 MAY-17 SEP-17 JAN-18 MAY-18 20 15 10 5 0 Vol. (mil) Price Making it official." (5/4/2018)
- 2. Needham & Company LLC analysts commented, "Tetraphase reported 4Q17 financial results yesterday after market close and we spoke w/ mgmt for an update. As a reminder, the company announced last month that the IV eravacycline Phase 3 IGNITE3 trial in complicated Urinary Tract Infections (cUTI) missed the primary endpoint. We do not expect the company to continue development in cUTI, nor to pursue development of an oral formulation of the drug. IV eravacycline is under review for complicated Intra- Abdominal Infections (cIAI) in both the U.S. and E.U. We expect approval by the 8/28/18 PDUFA date in the U.S. and in 2H18 in Europe. Maintain HOLD rating, based on concerns around commercial potential for lead asset IV eravacycline." (3/7/2018)
- 3. According to Zacks Investment Research, "Tetraphase Pharmaceuticals, Inc. is a life science company engaged in developing and commercializing tetracycline based drugs to treat drug-resistant infectious diseases, inflammation, and cancer. Its principal products include eravacycline, an intravenous and oral antibiotic for the treatment of multi-drug resistant Gram-negative infections. The Company's product under development includes eravacycline oral formulation, TP-834 and TP-271. Tetraphase Pharmaceuticals, Inc. is based in Watertown, Massachusetts. " (1/12/2018)
Who are some of Tetraphase Pharmaceuticals' key competitors?
Some companies that are related to Tetraphase Pharmaceuticals include CymaBay Therapeutics (CBAY), Homology Medicines (FIXX), ANI Pharmaceuticals Inc Common Stock (ANIP), Dicerna Pharmaceuticals (DRNA), Arcus Biosciences (RCUS), Dova Pharmaceuticals (DOVA), Five Prime Therapeutics (FPRX), Rigel Pharmaceuticals (RIGL), Aduro BioTech (ADRO), ChemoCentryx (CCXI), Lannett (LCI), Odonate Therapeutics (ODT), Ziopharm Oncology (ZIOP), BeyondSpring (BYSI) and Keryx Biopharmaceuticals (KERX).
Who are Tetraphase Pharmaceuticals' key executives?
Tetraphase Pharmaceuticals' management team includes the folowing people:
- Mr. Guy MacDonald B.Sc., B.Sc, CEO, Pres & Director (Age 59)
- Mr. Christopher Watt, Principal Financial Officer & Principal Accounting Officer (Age 53)
- Dr. Jacques Dumas Ph.D., Chief Scientific Officer (Age 52)
- Ms. Maria D. Stahl, Sr. VP & Gen. Counsel (Age 47)
- Mr. Larry G. Edwards, Chief Operating Officer
Has Tetraphase Pharmaceuticals been receiving favorable news coverage?
Media stories about TTPH stock have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies negative and positive press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Tetraphase Pharmaceuticals earned a media sentiment score of 0.15 on Accern's scale. They also assigned news stories about the biopharmaceutical company an impact score of 49.00 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term.
Who are Tetraphase Pharmaceuticals' major shareholders?
Tetraphase Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.80%), Dimensional Fund Advisors LP (3.55%), Candriam Luxembourg S.C.A. (1.01%), UBS Group AG (0.71%), A.R.T. Advisors LLC (0.51%) and California Public Employees Retirement System (0.43%). Company insiders that own Tetraphase Pharmaceuticals stock include Jacques Dumas and L Patrick Gage. View Institutional Ownership Trends for Tetraphase Pharmaceuticals.
Which institutional investors are selling Tetraphase Pharmaceuticals stock?
Which institutional investors are buying Tetraphase Pharmaceuticals stock?
How do I buy shares of Tetraphase Pharmaceuticals?
Shares of TTPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Tetraphase Pharmaceuticals' stock price today?
One share of TTPH stock can currently be purchased for approximately $3.76.
How big of a company is Tetraphase Pharmaceuticals?
Tetraphase Pharmaceuticals has a market capitalization of $187.29 million and generates $9.67 million in revenue each year. The biopharmaceutical company earns $-114,750,000.00 in net income (profit) each year or ($2.63) on an earnings per share basis. Tetraphase Pharmaceuticals employs 78 workers across the globe.
How can I contact Tetraphase Pharmaceuticals?
Tetraphase Pharmaceuticals' mailing address is 480 ARSENAL STREET SUITE 110, WATERTOWN MA, 02472. The biopharmaceutical company can be reached via phone at 617-715-3600 or via email at [email protected]
MarketBeat Community Rating for Tetraphase Pharmaceuticals (TTPH)
MarketBeat's community ratings are surveys of what our community members think about Tetraphase Pharmaceuticals and other stocks. Vote "Outperform" if you believe TTPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TTPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
9 Wall Street analysts have issued ratings and price targets for Tetraphase Pharmaceuticals in the last 12 months. Their average twelve-month price target is $7.1429, suggesting that the stock has a possible upside of 89.97%. The high price target for TTPH is $11.00 and the low price target for TTPH is $3.00. There are currently 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.67 | 2.67 | 2.63 | 2.80 |
| Ratings Breakdown: | 0 Sell Rating(s)
3 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $7.1429 | $7.1429 | $10.1429 | $17.00 |
| Price Target Upside: | 89.97% upside | 145.46% upside | 361.04% upside | 167.30% upside |
Tetraphase Pharmaceuticals (NASDAQ:TTPH) Consensus Price Target History
Tetraphase Pharmaceuticals (NASDAQ:TTPH) Analyst Ratings History
Show:
(Data available from 5/25/2016 forward)
Tetraphase Pharmaceuticals (NASDAQ:TTPH) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Tetraphase Pharmaceuticals (NASDAQ TTPH) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 4.10%
Institutional Ownership Percentage: 46.51%
Tetraphase Pharmaceuticals (NASDAQ TTPH) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 1/30/2018 | Jacques Dumas | Insider | Sell | 8,750 | $6.22 | $54,425.00 | 8,750 |  |
| 1/9/2018 | Jacques Dumas | Insider | Sell | 7,167 | $6.21 | $44,507.07 | | |
| 11/29/2017 | L Patrick Gage | Director | Buy | 3,880 | $6.45 | $25,026.00 | 38,880 | |
| 10/31/2017 | Jacques Dumas | Insider | Sell | 8,750 | $6.03 | $52,762.50 | 8,750 | |
| 8/22/2017 | Jacques Dumas | Insider | Sell | 17,500 | $6.00 | $105,000.00 | 17,500 | |
| 8/17/2017 | Jacques Dumas | Insider | Sell | 7,155 | $5.86 | $41,928.30 | | |
| 3/15/2017 | L Patrick Gage | Director | Buy | 11,000 | $7.49 | $82,390.00 | 35,000 | |
| 9/1/2015 | Guy Macdonald | insider | Sell | 10,000 | $41.57 | $415,700.00 | 52,000 | |
| 8/14/2015 | David Charles Lubner | CFO | Sell | 9,500 | $42.92 | $407,740.00 | | |
| 8/13/2015 | Patrick Taylor Horn | Insider | Sell | 10,000 | $44.69 | $446,900.00 | | |
| 8/12/2015 | L Patrick Gage | Director | Sell | 15,000 | $45.00 | $675,000.00 | | |
| 7/20/2015 | Guy Macdonald | Insider | Sell | 15,000 | $50.72 | $760,800.00 | | |
| 7/14/2015 | David Charles Lubner | CFO | Sell | 7,500 | $48.92 | $366,900.00 | | |
| 7/13/2015 | Patrick Taylor Horn | Insider | Sell | 10,000 | $48.93 | $489,300.00 | | |
| 7/6/2015 | John Craig Thompson | COO | Sell | 10,000 | $47.91 | $479,100.00 | | |
| 7/1/2015 | Guy Macdonald | Insider | Sell | 10,000 | $47.92 | $479,200.00 | | |
| 6/15/2015 | David Charles Lubner | CFO | Sell | 17,500 | $41.45 | $725,375.00 | | |
| 6/15/2015 | John Craig Thompson | COO | Sell | 10,000 | $41.51 | $415,100.00 | | |
| 6/8/2015 | John Craig Thompson | COO | Sell | 22,499 | $43.26 | $973,306.74 | | |
| 6/1/2015 | Guy Macdonald | Insider | Sell | 16,087 | $41.89 | $673,884.43 | | |
| 5/11/2015 | Guy Macdonald | Insider | Sell | 20,000 | $41.51 | $830,200.00 | | |
| 1/20/2015 | Guy Macdonald | Insider | Sell | 34,135 | $36.59 | $1,248,999.65 | | |
| 10/2/2014 | John Gordon Freund | Director | Sell | 247,734 | $20.88 | $5,172,685.92 | | |
| 10/1/2014 | John Gordon Freund | Director | Sell | 142,146 | $20.84 | $2,962,322.64 | | |
| 9/30/2014 | John Gordon Freund | Director | Sell | 152,266 | $20.18 | $3,072,727.88 | | |
| 9/29/2014 | John Gordon Freund | Director | Sell | 95,648 | $20.19 | $1,931,133.12 | | |
| 9/23/2014 | Guy Macdonald | Insider | Sell | 10,000 | $18.47 | $184,700.00 | | |
| 9/17/2014 | Guy Macdonald | Insider | Sell | 10,000 | $18.00 | $180,000.00 | | |
| 9/17/2014 | John Gordon Freund | Director | Sell | 144,356 | $17.21 | $2,484,366.76 | | |
| 9/12/2014 | John Gordon Freund | Director | Sell | 55,644 | $17.01 | $946,504.44 | | |
| 9/8/2014 | John Gordon Freund | Director | Sell | 16,700 | $15.01 | $250,667.00 | | |
| 9/4/2014 | John Gordon Freund | Director | Sell | 183,300 | $15.05 | $2,758,665.00 | | |
| 9/3/2014 | John Gordon Freund | Director | Sell | 142,100 | $15.04 | $2,137,184.00 | | |
| 8/20/2014 | Guy Macdonald | Insider | Sell | 10,000 | $11.59 | $115,900.00 | | |
| 7/18/2014 | Guy Macdonald | Insider | Sell | 15,000 | $10.61 | $159,150.00 | | |
| 6/23/2014 | John Gordon Freund | Director | Sell | 47,184 | $13.77 | $649,723.68 | | |
| 6/20/2014 | John Gordon Freund | Director | Sell | 152,816 | $13.39 | $2,046,206.24 | | |
| 6/17/2014 | David Charles Lubner | CFO | Sell | 13,530 | $12.51 | $169,260.30 | | |
| 6/17/2014 | Guy Macdonald | Insider | Sell | 15,000 | $12.28 | $184,200.00 | | |
| 5/19/2014 | Guy Macdonald | Insider | Sell | 15,000 | $9.00 | $135,000.00 | | |
| 5/19/2014 | Steven Ph.D. Gullans | Director | Buy | 25,000 | $9.24 | $231,000.00 | 25,000 | |
| 5/14/2014 | L Patrick Gage | Director | Buy | 5,000 | $9.25 | $46,250.00 | 5,000 | |
| 4/14/2014 | Guy Macdonald | Insider | Sell | 15,000 | $9.69 | $145,350.00 | | |
| 3/20/2014 | Joyce Sutcliffe | SVP | Sell | 11,494 | $12.41 | $142,640.54 | 17,242 | |
| 3/6/2014 | David Charles Lubner | CFO | Sell | 4,510 | $13.65 | $61,561.50 | 91,993 | |
| 2/20/2014 | Joyce Sutcliffe | SVP | Sell | 11,494 | $14.00 | $160,916.00 | 28,736 | |
| 2/12/2014 | David Charles Lubner | CFO | Sell | 4,506 | $13.92 | $62,723.52 | 96,503 | |
| 2/7/2014 | David Charles Lubner | CFO | Sell | 9,928 | $14.22 | $141,176.16 | 101,009 | |
| 2/5/2014 | Joyce Sutcliffe | SVP | Sell | 11,494 | $13.93 | $160,111.42 | 40,230 | |
| 9/18/2013 | Ventures Vi Lp Cmea | major shareholder | Sell | 100,000 | $10.20 | $1,020,000.00 | | |
| 9/17/2013 | Ventures Vi Lp Cmea | major shareholder | Sell | 53,468 | $9.26 | $495,113.68 | | |
| 3/25/2013 | John Gordon Freund | Director | Buy | 681,012 | $7.00 | $4,767,084.00 | | |
| 3/25/2013 | Medical Fund Lp Excel | Major Shareholder | Buy | 496,121 | $7.00 | $3,472,847.00 | | |
| 3/20/2013 | Fmr Llc | Insider | Buy | 642,857 | $7.00 | $4,499,999.00 | | |
(Data available from 1/1/2013 forward)
Tetraphase Pharmaceuticals (NASDAQ TTPH) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Tetraphase Pharmaceuticals, My Favorite 2H 2018 Biotech
seekingalpha.com - May 23 at 4:47 PM |
 | Tetraphase Pharmaceuticals Inc. (TTPH) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - May 23 at 1:30 AM |
| Tetraphase Pharmaceuticals (TTPH) Presents At 2018 UBS Global Healthcare Conference - Slideshow
seekingalpha.com - May 22 at 4:32 PM |
 | Tetraphase Pharmaceuticals to Present Eravacycline and TP-6076 Data at ASM Microbe 2018
finance.yahoo.com - May 21 at 9:04 AM |
| Tetraphase Pharmaceuticals Inc. (TTPH) Expected to Post Quarterly Sales of $2.23 Million
www.americanbankingnews.com - May 18 at 5:00 AM |
| Tetraphase Pharmaceuticals Inc. (TTPH) Expected to Post Earnings of -$0.36 Per Share
www.americanbankingnews.com - May 16 at 3:12 AM |
| Tetraphase Pharmaceuticals EPS in-line, misses on revenue
seekingalpha.com - May 4 at 4:35 PM |
| Tetraphase Pharmaceuticals (TTPH) Posts Quarterly Earnings Results, Beats Expectations By $0.04 EPS
www.americanbankingnews.com - May 4 at 3:32 PM |
| HC Wainwright Reiterates Buy Rating for Tetraphase Pharmaceuticals (TTPH)
www.americanbankingnews.com - May 4 at 3:17 PM |
 | Tetraphase Pharmaceuticals Reports First Quarter 2018 Financial Results and Recent Highlights
globenewswire.com - May 4 at 9:11 AM |
| Tetraphase: 1Q Earnings Snapshot
finance.yahoo.com - May 4 at 9:11 AM |
| Tetraphase Pharmaceuticals Reports First Quarter 2018 Financial Results and Recent Highlights
finance.yahoo.com - May 3 at 4:34 PM |
| $1.88 Million in Sales Expected for Tetraphase Pharmaceuticals Inc. (TTPH) This Quarter
www.americanbankingnews.com - April 30 at 2:58 AM |
| Zacks: Analysts Anticipate Tetraphase Pharmaceuticals Inc. (TTPH) to Post -$0.41 EPS
www.americanbankingnews.com - April 28 at 3:14 PM |
| Tetraphase Pharmaceuticals Inc. (TTPH) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - April 28 at 1:34 AM |
| Tetraphase Pharmaceuticals (TTPH) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - April 25 at 6:32 AM |
| Tetraphase Pharmaceuticals to Present Data at the 38th Annual Meeting of the Surgical Infection Society
finance.yahoo.com - April 19 at 9:13 AM |
| Tetraphase Pharmaceuticals’ Cash Flow and Price Performance
finance.yahoo.com - April 19 at 9:13 AM |
| A Look at Tetraphase Pharmaceuticals’ Target Market
finance.yahoo.com - April 18 at 4:52 PM |
| Exploring Tetraphase Pharmaceuticals’ Financial Performance
finance.yahoo.com - April 18 at 4:52 PM |
| Blog Exposure - Tetraphase Pharma Announced Data Presentations from IGNITE4 Study at 28th European Congress of Clinical Microbiology and Infectious Diseases
finance.yahoo.com - April 16 at 9:09 AM |
| Tetraphase Pharmaceuticals Inc. (TTPH) Expected to Post Quarterly Sales of $1.88 Million
www.americanbankingnews.com - April 13 at 2:33 AM |
| Tetraphase Pharmaceuticals to Present Data at 28th European Congress of Clinical Microbiology and Infectious Diseases
finance.yahoo.com - April 12 at 10:06 AM |
| Zacks: Analysts Expect Tetraphase Pharmaceuticals Inc. (TTPH) Will Post Earnings of -$0.41 Per Share
www.americanbankingnews.com - April 11 at 3:10 PM |
| Tetraphase Pharmaceuticals (TTPH) Lowered to "Sell" at BidaskClub
www.americanbankingnews.com - April 10 at 8:54 PM |
| Tetraphase Pharmaceuticals (TTPH) Presents At H. C. Wainwright Global Life Sciences Conference - Slideshow
seekingalpha.com - April 10 at 4:38 PM |
| Zacks Investment Research Downgrades Tetraphase Pharmaceuticals (TTPH) to Sell
www.americanbankingnews.com - April 6 at 3:00 PM |
| Tetraphase Pharmaceuticals Inc (TTPH) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - April 3 at 1:33 AM |
| Tetraphase Pharmaceuticals (TTPH) Raised to Buy at Gabelli
www.americanbankingnews.com - March 29 at 9:19 AM |
| $1.88 Million in Sales Expected for Tetraphase Pharmaceuticals Inc (TTPH) This Quarter
www.americanbankingnews.com - March 27 at 5:25 AM |
| Zacks: Analysts Anticipate Tetraphase Pharmaceuticals Inc (TTPH) to Announce -$0.41 EPS
www.americanbankingnews.com - March 25 at 5:15 PM |
 | This Morning's Technical Outlook on Generic Drugs Stocks -- Ironwood Pharma, Pacira Pharma, pSivida, and ... - PR Newswire (press release)
www.prnewswire.com - March 21 at 10:21 AM |
| Tetraphase Pharmaceuticals to Present at 17th Annual Needham Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - March 20 at 4:30 PM |
| Tetraphase Pharmaceuticals to Present at 17th Annual Needham Healthcare Conference
finance.yahoo.com - March 20 at 4:30 PM |
| SunTrust Banks Brokers Boost Earnings Estimates for Tetraphase Pharmaceuticals Inc (TTPH)
www.americanbankingnews.com - March 12 at 1:21 AM |
| $2.27 Million in Sales Expected for Tetraphase Pharmaceuticals Inc (TTPH) This Quarter
www.americanbankingnews.com - March 10 at 6:06 AM |
| Tetraphase Pharmaceuticals Inc (TTPH) to Post FY2018 Earnings of ($1.82) Per Share, B. Riley Forecasts
www.americanbankingnews.com - March 9 at 9:18 AM |
| Tetraphase Pharmaceuticals Inc (TTPH) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - March 9 at 1:42 AM |
| Tetraphase Pharmaceuticals (TTPH) Price Target Increased to $3.00 by Analysts at BMO Capital Markets
www.americanbankingnews.com - March 8 at 7:17 PM |
| B. Riley Comments on Tetraphase Pharmaceuticals Inc's FY2019 Earnings (TTPH)
www.americanbankingnews.com - March 8 at 12:53 PM |
| Is It The Right Time To Buy Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH)?
finance.yahoo.com - March 7 at 5:27 PM |
| Tetraphase Pharmaceuticals (TTPH) Given "Hold" Rating at Needham & Company LLC
www.americanbankingnews.com - March 7 at 4:36 PM |
| Tetraphase Pharmaceuticals (TTPH) Releases Earnings Results, Beats Estimates By $0.18 EPS
www.americanbankingnews.com - March 7 at 8:14 AM |
| Tetraphase Pharmaceuticals Reports Fourth Quarter and Full-Year 2017 Financial Results, Highlights Achievements and Key 2018 Milestones
finance.yahoo.com - March 6 at 4:56 PM |
| Tetraphase Pharmaceuticals Appoints Larry Edwards Chief Operating Officer - GlobeNewswire (press release)
globenewswire.com - March 3 at 5:21 PM |
 | Tetraphase Pharma (TTPH) Names Larry Edwards as Chief Operating Officer
www.streetinsider.com - March 2 at 9:10 AM |
| Tetraphase Pharmaceuticals Appoints Larry Edwards Chief Operating Officer
finance.yahoo.com - March 1 at 4:58 PM |
| Reviewing Emergent Biosolutions (EBS) and Tetraphase Pharmaceuticals (TTPH)
www.americanbankingnews.com - March 1 at 3:02 PM |
| Tetraphase Pharmaceuticals Inc (TTPH) Shares Sold by Hudson Bay Capital Management LP
www.americanbankingnews.com - March 1 at 12:03 PM |
| Priority Review For Tetraphase's Eravacycline A 'Key Positive,' Analyst Says
finance.yahoo.com - March 1 at 9:01 AM |
Tetraphase Pharmaceuticals (NASDAQ:TTPH) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Tetraphase Pharmaceuticals (NASDAQ:TTPH) Income Statement, Balance Sheet and Cash Flow Statement
Tetraphase Pharmaceuticals (NASDAQ TTPH) Stock Chart for Friday, May, 25, 2018
Loading chart…
